Evidence suggests that accelerated or premature aging occurs in bipolar disorder (BD). Those with BD die younger, develop aging related diseases earlier, and exhibit general declines in functioning and levels of independence faster than otherwise healthy individuals [1, 2] . One domain of aging-cognitive functioninghas received interest in recent years. There is well-established evidence that BD patients exhibit more cognitive deficits than comparable healthy control subjects [3] [4] [5] and older BD subjects also exhibit worse cognitive performance than younger BD subjects [6] [7] [8] . However, the evidence for these findings are derived primarily from cross-sectional studies; studies examining cognition using longitudinal data are scarce and, among those available, show mixed results. One study found that over a period of up to 3-years, there was no difference in trajectories of cognitive performance in BD vs. normal controls, but there was greater variability in BD than the control group for these trajectories [9] . Another study found that there were no group differences between BD and non-psychiatric comparison participants in the rate of cognitive decline, but BD who had more lifetime manic episodes showed more precipitous declines [10] . The findings of variability in cog-Bipolar disorder (BD) is thought to be associated with premature cognitive aging, but there has been relatively little research examining the role of sleep quality within this relationship. There is ample evidence for a link between sleep disturbance and cognitive decline in the general population as recent studies show this relationship longitudinally. However, there is a need to examine whether sleep disturbance in BD is associated with cognitive outcomes, and the ways in which sleep may impact premature cognitive aging. We first review the literature about early cognitive decline in BD, and the role disturbed sleep may play in this association. Second, we provide suggestions on future research to examine the role of sleep in cognitive aging in BD and identify the key areas needing further research with the purpose of determining ways to improve the cognitive health and overall functioning of those with BD.
CIM nitive trajectories in BD suggests that BD in itself may not confer to increased risk for cognitive decline. However, it may be possible that there are subgroups of BD patients with unique risk profiles, such as greater illness chronicity, that show accelerated cognitive decline.
One important risk factor receiving increased attention in recent years is that of sleep disturbances, which is a hallmark symptom of BD. Past studies estimate over 70% of BD patients experience some sleep disturbance [11] . There is ample evidence to support the hypothesis that sleep disturbance is a risk factor for accelerated cognitive decline in BD. Epidemiological studies in the general population show sleep disturbance to be associated with future cognitive decline [12] . There is also emerging research suggesting a biological link between sleep and dementia pathologystudies of rodents [13] and humans [14, 15] show sleep may impart clearance of waste products in the brain built up during the day that may ward against development of dementia biomarkers (e.g., beta-amyloid deposits). There are some cross-sectional studies showing sleep disturbances in BD to be associated with impairments in domains of cognition, primarily attention and process-ing speed [16] , but recent reviews have suggested poor sleep may be a factor that drives the poorer cognition seen in BD [17, 18] . Given that sleep disturbances are ingrained so profoundly within BD, the high-risk of cognitive impairments in this group, and crosssectional evidence of impairments in cognition in BD, there is a need for more research identifying the potential implications for sleep as a contributor to accelerated cognitive aging in BD patients.
Future studies that examine sleep and longitudinal cognitive decline in BD require careful measurement of sleep and cognition over long durations of time. With the growth of wrist actigraphy and consumer wearables (e.g., Fitbits) to measure sleep quality, one can get an accurate representation of sleep over multiple nights and in the usual sleeping environment of their bedroom, which may be hard to assess in a clinical sleep lab. Additionally, careful repeated assessment of cognitive functioning that accounts for any practice effects or are robust to assessing changes over time would also prove useful. New advances in mobile cognitive assessments-instantaneous real-time assessment of cognition via smartphone devices-may be useful in determining the impact of acute cognitive symptoms on long-term cognitive outcomes. Additionally, neuroimaging of brain health through MRI and fMRI may help identify longitudinal change in brain structure that could identify sub-clinical manifestations of cognitive decline in this group.
More research is also needed in understanding the mechanisms for the link between sleep and cognitive aging in BD. Given the unique characteristics of BD illness, the mechanistic link may be different than that in healthy samples. For example, BD has been shown to be associated with elevated levels of proinflammatory biomarkers, and inflammation is known to be associated with both sleep [19] and cognitive impairments [20] . Other possible mechanisms warranting examination are lifestyle and health behaviors. Better understanding the mechanisms (both biological and behavioral) may advance our ability to intervene at important inflection points in the life course of BD patients.
In this context, there is also a need for further clinical and intervention research to extend the period of cognitively healthy life in BD. We need more research in the identification of the effective therapies that target sleep-related problems specifically in BD, and in their impact on longitudinal cognitive trajectories. One such therapy, Interpersonal and Social Rhythm Therapy [21] , seeks to improve awareness of circadian patterns to help regulate mood fluctuations. Studies examining whether receipt of this and other related therapies protect against accelerated cognitive decline could assist in prevention efforts in this group. We also need more studies using implementation science approaches to evaluate how such therapies work in real-world healthcare systems and determine how to better integrate them in the contexts of mental health clinics. Such efforts would promote rapid dissemination of the therapies that work, and subsequently evaluate the effect on mental healthcare systemwide outcomes.
There remains much to be known about accelerated cognitive decline and the risk factors that may increase this risk in BD. Given the combination of evidence of cognitive decline due to sleep and the high prevalence of sleep disturbance in BD patients, there is reason to focus on sleep as a potential risk factor. However, it would also be important to examine whether sleep as a risk factor for accelerated cognitive decline in BD may in fact be multivariate-a unique combination of sleep with other factors that increase risk in an additive or multiplicative fashion. Such additional risk factors could be the number of past manic or depressive episodes or other measures of chronicity of illness duration. Filling in the gaps in research discussed here, and adequately addressing these issues in real-world healthcare systems, could result in positive public health outcomes and help promote independence for BD patients and others with serious mental illness.
